{"id":"NCT01313312","sponsor":"Ipsen","briefTitle":"Dysport® Adult Upper Limb Spasticity Extension Study","officialTitle":"A Phase III, Multicentre, Prospective, Open Label Extension Study to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2011-03-11","resultsPosted":"2017-06-07","lastUpdate":"2022-09-28"},"enrollment":258,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Nervous System Disorders"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]}],"arms":[{"label":"Total Dysport®","type":"EXPERIMENTAL"}],"summary":"The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.","primaryOutcome":{"measure":"Assessment of the Long-term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to Week 52","effectByArm":[{"arm":"Total Dysport®","deltaMin":102,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":34,"countries":["United States","Belgium","Czechia","France","Hungary","Italy","Poland","Russia","Slovakia"]},"refs":{"pmids":["29781237"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":254},"commonTop":["Fall","Pain in extremity","Muscular weakness","Arthralgia","Fatigue"]}}